c-myc oncoprotein levels in bladder cancer.
The protein coded by the oncogene c-myc, p62c-myc, was measured using monoclonal antibodies and flow cytometry in nuclei derived from paraffin-wax sections of transitional cell carcinomas of the human bladder. Superficial disease (stages pTa and pT1) which did not recur within 5 years of diagnosis had significantly higher oncoprotein levels than those which did recur or were muscle-invasive (stage pT2 or greater) at presentation (P less than 0.01). These preliminary findings indicate that oncoprotein levels might have prognostic significance for bladder cancer.
Masters
J R
JR
Institute of Urology, St. Paul's Hospital, London, United Kingdom.
Vesey
S G
SG
Munn
C F
CF
Evan
G I
GI
Watson
J V
JV
D000911:Antibodies, Monoclonal; D002295:Carcinoma, Transitional Cell / Q000235:genetics / Q000378:metabolism*; D004247:DNA / Q000235:genetics / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D011379:Prognosis; D011518:Proto-Oncogene Proteins / Q000235:genetics / Q000378:metabolism*; D016271:Proto-Oncogene Proteins c-myc; D001749:Urinary Bladder Neoplasms / Q000235:genetics / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D011518:Proto-Oncogene Proteins; D016271:Proto-Oncogene Proteins c-myc; D004247:DNA